Mechanism of Action
Angiogenesis & VEGF Modulation
Promotion of new blood vessel formation and upregulation of VEGF signaling at injury sites.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Compounds
1
Total studies
128
Human studies
3
FDA approved
0
Overview
Angiogenesis-modulating peptides promote the formation of new capillaries at sites of tissue damage. They upregulate vascular endothelial growth factor (VEGF) expression, enhance endothelial cell migration, and improve blood flow to injured tissues — all critical steps in tendon, ligament, and wound healing.
Angiogenesis-driven tissue repair requires coordinated endothelial-cell proliferation, migration, tube formation, and pericyte recruitment. VEGF-A is the master regulator, with BPC-157 documented to upregulate VEGF expression across multiple tissue types in animal models. The pathway also intersects with nitric oxide signaling (NO modulates vessel tone and permeability) and with growth factors including FGF-2 and PDGF. Therapeutic angiogenesis differs from tumor angiogenesis in its controlled resolution — successful wound healing ends angiogenesis, whereas tumor angiogenesis is sustained.
Receptor & signaling detail
VEGF receptors (VEGFR-1, VEGFR-2, VEGFR-3) are receptor tyrosine kinases on endothelial cells. VEGFR-2 drives most pro-angiogenic signaling. BPC-157 does not appear to bind VEGF receptors directly but rather upregulates VEGF expression via incompletely characterized upstream pathways.
How it works
- 1Upregulates VEGF expression at injury sites.
- 2Enhances endothelial cell proliferation and migration.
- 3Promotes tube formation and new capillary networks.
- 4Modulates nitric oxide signaling to improve local blood flow.
- 5Supports fibroblast recruitment and extracellular matrix remodeling.
Downstream clinical effects
- Accelerated wound closure
- Improved tendon and ligament repair
- Enhanced gut mucosal healing
- Neuroprotection in CNS injury models
Documented clinical implications
- Accelerated wound closure in rodent tissue-repair models
- Improved tendon and ligament healing in preclinical studies
- GI ulcer protection (NSAID-induced, ethanol-induced models)
- Neuroprotection in animal stroke and spinal-cord injury models
Limitations & mechanism-driven side effects
- Human clinical trial data is very limited — most evidence is preclinical
- No FDA-approved indication for any angiogenesis-modulating peptide
- BPC-157 placed on FDA Category 2 list in 2023
- Potential concern about promoting unwanted angiogenesis in occult malignancy (unproven)
Discovery & development
BPC-157 was derived in the 1990s from a gastric juice protein identified for its cytoprotective properties. The 15-amino-acid sequence has been studied extensively in animal models of tendon, ligament, gut, and CNS injury.
Peptides using this mechanism
Evidence status
BPC-157 is the most-studied example. Animal evidence is extensive and consistent; controlled human trials remain limited.
Frequently asked questions
How does BPC-157 promote healing?
Preclinical data points to upregulation of VEGF expression, enhanced endothelial cell migration, and modulation of nitric oxide signaling at injury sites. Controlled human evidence is limited.
Is there human evidence for BPC-157 in injury recovery?
Very limited. A small number of human pilot reports exist but are not adequate to establish efficacy for specific injuries. The vast majority of evidence is from animal models.
Does BPC-157 stimulate tumor growth?
There are no published reports of tumor promotion by BPC-157, but angiogenesis modulation theoretically could support pathological vessel formation in occult malignancy. This concern is not resolved.
Why is BPC-157 on the FDA Category 2 list?
The FDA cited potential immune reactions, manufacturing impurities, and a lack of human safety data when placing BPC-157 on the 503A Category 2 list in late 2023, prohibiting compounding for human use.
Relevant best-of guides
Best Peptides for Muscle Recovery & Injury Healing
Peptides most studied for tissue repair, tendon healing, and post-exercise recovery — ranked by the quality of supporting research.
Best Peptides for Skin & Hair
Peptides with dermatological evidence — ranked by human skin-biology research.
Best Peptides for Gut Health & Leaky Gut
Peptides investigated for intestinal repair and gut barrier function — ranked by research depth.
Best Peptides for Athletic Performance
Peptides associated with athletic performance contexts — ranked by evidence and WADA status.
Related articles
Peptides for Women: Safety, Benefits, and What’s Different
Deep Dive · 14 min
FDA Sets July 23–24 Meeting to Review BPC-157, TB-500, and 5 More Peptides for Compounding Access
Regulatory · 12 min
RFK Jr. Announces 14 Peptides Moving Back to Category 1: What It Means
Regulatory · 7 min
FDA Category 2 Peptide Ban: The Complete Guide
Regulatory · 7 min
Peptide Compounding in 2026: What Patients Need to Know
Guide · 5 min